A polymerizable compound has a practical low melting point, excellent solubility in a general-purpose solvent, and can produce an optical film at low cost, exhibits low reflected luminance, and achieves uniform conversion of polarized light over a wide wavelength band, an optically anisotropic article.

A polymerizable compound has a practical low melting point, excellent solubility in a general-purpose solvent, and can produce an optical film at low cost, exhibits low reflected luminance, and achieves uniform conversion of polarized light over a wide wavelength band, an optically anisotropic article.

A polymerizable compound has a practical low melting point, excellent solubility in a general-purpose solvent, and can produce an optical film at low cost, exhibits low reflected luminance, and achieves uniform conversion of polarized light over a wide wavelength band, an optically anisotropic article. A carbonyl compound is useful as a raw material for producing the polymerizable compound. (In the formula (I), Y.sup.1 to Y.sup.8 represent C(O)O, G.sup.1 and G.sup.2 represent a C.sub.1-20 divalent linear aliphatic group, Z.sup.1 and Z.sup.2 represent a C.sub.2-10 alkenyl group that is unsubstituted, or substituted with a halogen atom, A.sup.x represents a C.sub.2-30 organic group with at least one aromatic ring, A.sup.y represents a hydrogen atom or C.sub.1-20 alkyl group, A.sup.1 represents a trivalent aromatic group, A.sup.2 and A.sup.3 represent a C.sub.3-30 divalent alicyclic hydrocarbon group, A.sup.4 and A.sup.5 represent a C.sub.6-30 divalent aromatic group or the like, and Q.sup.1 represents a hydrogen atom.) ##STR00001##

A polymerizable compound has a practical low melting point, excellent solubility in a general-purpose solvent, and can produce an optical film at low cost, exhibits low reflected luminance, and achieves uniform conversion of polarized light over a wide wavelength band, an optically anisotropic article. A carbonyl compound is useful as a raw material for producing the polymerizable compound. (In the formula (I), Y.sup.1 to Y.sup.8 represent C(O)O, G.sup.1 and G.sup.2 represent a C.sub.1-20 divalent linear aliphatic group, Z.sup.1 and Z.sup.2 represent a C.sub.2-10 alkenyl group that is unsubstituted, or substituted with a halogen atom, A.sup.x represents a C.sub.2-30 organic group with at least one aromatic ring, A.sup.y represents a hydrogen atom or C.sub.1-20 alkyl group, A.sup.1 represents a trivalent aromatic group, A.sup.2 and A.sup.3 represent a C.sub.3-30 divalent alicyclic hydrocarbon group, A.sup.4 and A.sup.5 represent a C.sub.6-30 divalent aromatic group or the like, and Q.sup.1 represents a hydrogen atom.) ##STR00001##

The polymerizable liquid crystal compound has reverse wavelength dispersion or low wavelength dispersion and has high solubility in various solvents. The polymerizable liquid crystal compound provides an optically anisotropic body having high adhesiveness to substrates (or alignment films), by adding the polymerizable liquid crystal compound to a polymerizable composition and polymerizing the polymerizable composition using ultraviolet light. The invention provides a polymerizable composition containing the polymerizable liquid crystal compound having reverse wavelength dispersion or low wavelength dispersion, a polymer obtained by polymerizing the polymerizable composition, and an optically anisotropic body using the polymer. The present invention provides a polymerizable low wavelength dispersion or polymerizable reverse wavelength dispersion compound having in the molecule a partial structure represented by the general formula (AO-1); and also provides a composition containing the compound, a polymer obtained by polymerizing the composition, and an optically anisotropic body and the like using the polymer.

##STR00001##

Compounds having General Formula (I) or General Formula (II):

##STR00001##

in which R.sup.1 is chosen from C.sub.1 to C.sub.10 aliphatic or heteroaliphatic groups, optionally substituted with one or more aryl groups, substituted aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof; R.sup.2 is chosen from aromatic moieties, substituted aromatic moieties, heteroaromatic moieties, substituted heteroaromatic moieties, and coumarin; R.sup.3 is chosen from H, C.sub.1 to C.sub.10 aliphatic or heteroaliphatic groups, phenyl, or substituted phenyl, wherein the aliphatic or heteroaliphatic groups are optionally substituted with one or more phenyl groups, aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof, and wherein the aliphatic or heteroaliphatic groups are optionally bonded to R.sup.2 to form a ring; X is S or O; and Y is S or NH, may be used in pharmaceutical compositions that modify of biological signaling processes or as reagents for biological assays.

Compounds having General Formula (I) or General Formula (II):

##STR00001##

in which R.sup.1 is chosen from C.sub.1 to C.sub.10 aliphatic or heteroaliphatic groups, optionally substituted with one or more aryl groups, substituted aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof; R.sup.2 is chosen from aromatic moieties, substituted aromatic moieties, heteroaromatic moieties, substituted heteroaromatic moieties, and coumarin; R.sup.3 is chosen from H, C.sub.1 to C.sub.10 aliphatic or heteroaliphatic groups, phenyl, or substituted phenyl, wherein the aliphatic or heteroaliphatic groups are optionally substituted with one or more phenyl groups, aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof, and wherein the aliphatic or heteroaliphatic groups are optionally bonded to R.sup.2 to form a ring; X is S or O; and Y is S or NH, may be used in pharmaceutical compositions that modify of biological signaling processes or as reagents for biological assays.

Compounds for inhibiting human platelet-type 12-(S)-lipoxygenase (12-LOX) are provided. Compounds according to certain embodiments modulate platelet activation and hemostasis. In some embodiments, compounds described herein modulate platelet activation mediated by immune receptor, Fc?RIIa. Methods for modulating platelet reactivity (e.g., following vascular insult or injury) with the compounds are also described. Methods for treating or preventing a platelet-type 12-(S)-lipoxygenase (12-LOX)-mediated disease are also provided. Compositions for practicing the subject methods are also described.

Compounds for inhibiting human platelet-type 12-(S)-lipoxygenase (12-LOX) are provided. Compounds according to certain embodiments modulate platelet activation and hemostasis. In some embodiments, compounds described herein modulate platelet activation mediated by immune receptor, Fc?RIIa. Methods for modulating platelet reactivity (e.g., following vascular insult or injury) with the compounds are also described. Methods for treating or preventing a platelet-type 12-(S)-lipoxygenase (12-LOX)-mediated disease are also provided. Compositions for practicing the subject methods are also described.

The present disclosure relates to a plurality of host materials comprising at least one first host compound and at least one second host compound and an organic electroluminescent device comprising the same. By comprising the specific combination of the compound according to the present disclosure as host materials, an organic electroluminescent device having low driving voltage, high luminous efficiency, and long lifespan characteristics can be prepared.